{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=26", "query": { "intervention": "dose level 1", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 29101, "total_pages": 2911, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T19:34:38.967Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01131923", "title": "Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Amlodipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dr. Reddy's Laboratories Limited, India", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 26, "start_date": "2002-10", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2010-06-14", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01131923" }, { "nct_id": "NCT00002680", "title": "Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "megestrol acetate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1994-02", "completion_date": "2000-12", "has_results": false, "last_update_posted_date": "2013-07-24", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002680" }, { "nct_id": "NCT04925479", "title": "Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Leukemia, Philadelphia Positive" ], "interventions": [ { "name": "Asciminib Pediatric formulation group", "type": "DRUG" }, { "name": "Asciminib Adult formulation group", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 46, "start_date": "2021-12-27", "completion_date": "2031-10-02", "has_results": false, "last_update_posted_date": "2026-11-09", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 3, "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925479" }, { "nct_id": "NCT07221188", "title": "A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-alcoholic Fatty Liver Disease" ], "interventions": [ { "name": "Efimosfermin Alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1250, "start_date": "2025-12-12", "completion_date": "2028-03-24", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 57, "location_summary": "Arcadia, California • Covina, California • Los Angeles, California + 44 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Covina", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221188" }, { "nct_id": "NCT00818961", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "40 Years to 72 Years" }, "enrollment_count": 36, "start_date": "2005-05", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00818961" }, { "nct_id": "NCT04494386", "title": "Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Covid19", "Corona Virus Infection", "SARS-CoV Infection", "ARDS", "Coronavirus" ], "interventions": [ { "name": "Umbilical Cord Lining Stem Cells (ULSC)", "type": "BIOLOGICAL" }, { "name": "Placebo (carrier control)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Restem, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-12-23", "completion_date": "2023-05-12", "has_results": false, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 2, "location_summary": "Miami, Florida • Sioux Falls, South Dakota", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04494386" }, { "nct_id": "NCT03997786", "title": "A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Moderate-to-severe Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "215 Months", "sex": "ALL", "summary": "6 Years to 215 Months" }, "enrollment_count": 135, "start_date": "2020-01-15", "completion_date": "2031-08-05", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 5, "location_summary": "Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03997786" }, { "nct_id": "NCT03996473", "title": "Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY 88-8223)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-03-06", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 1, "location_summary": "San Marcos, California", "locations": [ { "city": "San Marcos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03996473" }, { "nct_id": "NCT00602641", "title": "Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 306, "start_date": "2008-02-29", "completion_date": "2027-02-20", "has_results": true, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 389, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 255 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Marysville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00602641" }, { "nct_id": "NCT00942305", "title": "Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cytomegalovirus Infection" ], "interventions": [ { "name": "Brincidofovir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 239, "start_date": "2009-10", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-11-14T19:34:38.967Z", "location_count": 26, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00942305" } ] }